Investigating how kidney cancer cells use energy
Official title: Targeting the Warburg Effect in Kidney Cancer
Funded at Syracuse VA Medical Center · NIH-10701222 · Data updated 2026-11-12
This study is looking at how kidney cancer, especially in military personnel and their families, uses different ways to get energy and grow, with the goal of finding better treatments for those affected.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Syracuse VA Medical Center NIH-funded |
| Lab location | 1 site (Syracuse, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| NIH project number | 1I01BX006271-01 |
| Project ID | NIH-10701222 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with clear cell renal cell carcinoma, particularly those with a history of military service or exposure to known risk factors.
✕Less likely to help
Patients with other types of kidney cancer or those who do not have clear cell renal cell carcinoma may not benefit from this research.
What this research studies
This research focuses on understanding the Warburg Effect in kidney cancer, particularly clear cell renal cell carcinoma (ccRCC), which is known for its resistance to traditional treatments. The study aims to explore the unique metabolic pathways that cancer cells utilize to thrive, especially in military personnel and their families who may be at higher risk due to environmental exposures. By analyzing the biological mechanisms behind this cancer, the research seeks to identify new therapeutic strategies that could improve treatment outcomes for patients. The approach includes biochemical assays and cellular studies to uncover how these cancer cells manage energy production.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for kidney cancer, improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in targeting metabolic pathways in cancer treatment, suggesting that this approach could yield significant advancements.
Where this research is happening
-
Syracuse VA Medical Center
Syracuse, United States Active
Researchers
- Principal investigator: Mollapour, Mehdi — Syracuse VA Medical Center
- Study coordinator: Mollapour, Mehdi
Related research
Other NIH-funded projects on the same topics.
-
Maximizing anti-tumor immune responses in kidney cancer
A cutting-edge program at UT Southwestern aims to speed up better immunotherapy options for kidney cancer by studying how to activate both innate and adaptive immune responses.
-
Kidney Cancer Career Enhancement Program (CEP) at DF/HCC
A career-boosting program supports junior investigators studying kidney cancer to help them advance in basic, translational, and clinical work.
-
Kidney Cancer Development Program at DF/HCC
A funded program at Dana-Farber/Brigham and Women’s Kidney Cancer Center supports new ideas from researchers to improve understanding and treatment of kidney cancer.
-
Personalized antigens for kidney cancer therapy
This grant explores identifying and targeting tumor-specific antigens in kidney cancer to develop more effective, personalized immunotherapies.
-
Optimizing Anti-PD1 Therapy for High-Risk and Metastatic Kidney Cancer
A large cancer research grant is testing how best to use anti-PD-1 therapy to help people with high-risk and metastatic kidney cancer live longer and with fewer side effects.
-
Targeting the HIF2 Pathway in Kidney Cancer
A cancer treatment program aims to see if a drug called belzutifan can help people with a specific kind of kidney cancer whose growth is driven by the HIF2 pathway.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.